Ameriprise’s KalVista Pharmaceuticals KALV Stock Holding History

Ameriprise’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-229,984	Closed	-$4.63M	–	4180
2026 Q1	$4.63M	Buy	229,984 +195,055	+558%	+$3.14M	﹤0.01%	2483
2025 Q4	$564K	Sell	34,929 -520	-1%	-$6.89K	﹤0.01%	3578
2025 Q3	$432K	Sell	35,449 -909,676	-96%	-$12.6M	﹤0.01%	3678
2025 Q2	$10.7M	Buy	945,125 +905,053	+2,259%	+$11.1M	﹤0.01%	1767
2025 Q1	$462K	Sell	40,072 -13,310	-25%	-$136K	﹤0.01%	3520
2024 Q4	$452K	Buy	+53,382	New	+$553K	﹤0.01%	3559
2023 Q2	–	Sell	-13,131	Closed	-$103K	–	3957
2023 Q1	$103K	Buy	+13,131	New	+$98K	﹤0.01%	3825

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ameriprise's KALV Position: Q2 2026 in Review

Ameriprise sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 229,984 shares — an estimated $4.63M sold.

Ameriprise first reported a position in KALV in Q1 2023 and held it in 7 quarters. The position peaked at $10.7M in Q2 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Ameriprise reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ameriprise sold 229,984 KalVista Pharmaceuticals shares in Q2 2026, an estimated $4.63M.
Ameriprise first reported a position in KalVista Pharmaceuticals in Q1 2023 and held it in 7 quarters.
Ameriprise's KalVista Pharmaceuticals position peaked at $10.7M in Q2 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.